Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Boston Scientific Corp. resumed enrollment in the AVANT GUARD trial of the Farapulse pulse field ablation (PFA) system after a pause reported in October “to assess a few unanticipated observations.” ...

Boston Scientific Corporation (NYSE:BSX)宣布恢复其AVANT GUARD临床试验,该试验针对一组新的持续性心房颤动未经药物治疗的患者。此前该试验因需要评估观察结果而暂停,但经过仔细审查并与研究数据监测委员会协商后,试验招募将继续进行。 AVANT GUARD试验是Boston Scientific的一项重要研究,该公司以开发和生产用于介入医学专科的医疗器械而 ...

马萨诸塞州马尔伯勒 - Boston Scientific Corporation (NYSE: BSX) 今天公布了其ACURATE IDE临床试验的主要终点结果。该试验评估了ACURATE neo2™主动脉瓣系统在各种手术风险类别的严重主动脉狭窄患者中的表现。这些发现在2024年Transcatheter Cardiovascular Therapeutics® (TCT®)研讨会上公布。 该 ...

Boston Scientific’s BSX net income was $469 million, or 32 cents a share, down from $505 million, or 34 cents a share, in the ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech ...

Boston Scientific (NYSE:BSX) today announced that a study of its Acurate neo2 aortic valve system missed its primary endpoint ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

Boston Scientific ( NYSE: BSX) has agreed to acquire privately held medical technology company, Cortex, Inc.